Cell and Gene Therapy Market Projected to Reach $50 Billion by 2027 Amid Scaling Challenges

Cell and gene therapies (CGTs) are emerging as one of the fastest-growing sectors in healthcare, with projections estimating the market could reach $50 billion annually by 2027. Despite their potential to revolutionize medical science and improve countless lives, scaling these therapies for larger patient populations presents significant logistical, manufacturing, and supply chain challenges. As of mid-2022, over 3,600 CGTs were in development globally, yet fewer than two dozen have reached the market. Experts anticipate exponential growth in available treatments as advancements in genetic engineering expand therapeutic possibilities across diseases such as leukemia, hemophilia, and sickle cell disease.

Regulatory bodies are increasingly accommodating CGTs to support this growth. In the U.S., several FDA-led initiatives and new guidance documents for CGT development were introduced this year. Similarly, the UK released updated guidelines for advanced therapy medicinal products (ATMPs), which encompass cell, gene, and tissue therapies. Industry leaders suggest that developers focus on creating standardized approaches within product portfolios to reduce costs and streamline scalability. Collaboration among healthcare systems—including manufacturers, buyers, users, and patients—is also emphasized as a strategy to address systemic complexities.

Operational excellence is another critical factor for successful CGT launches due to intricate logistics involving clinical development, manufacturing processes, and supply chain management. Experts recommend assembling core teams early to ensure capabilities align with treatment requirements before commercialization begins. For example, Robert Sexton of Mustang Bio highlights the importance of “just-in-time” delivery models that require real-time capacity planning across multiple checkpoints—a process complicated by unpredictable patient arrival times.

Scaling up treatment capacity while avoiding overextension remains a key challenge for developers aiming to serve larger markets efficiently. Phased activation of treatment centers can mitigate risks associated with misestimating demand or exceeding organizational constraints. Michael Hirschmann from Legend Biotech underscores the importance of cross-functional strategic planning informed by market research and claims data to accurately assess patient populations eligible for specific therapies.

Safety monitoring is another essential consideration when expanding CGTs to broader patient groups. These therapies often require intensive oversight during administration due to potential side effects; however, experts predict advancements will reduce these requirements over time. Some gene therapies may eventually be administered in outpatient settings as safety protocols evolve—potentially enabling higher volumes of patients to receive treatment more quickly.

As thousands of novel CGTs progress through development pipelines worldwide, industry stakeholders continue exploring strategies for scalable solutions that balance innovation with operational feasibility while addressing regulatory demands and patient needs effectively.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: December 8, 2022

Author

Mark Chiang